Search
forLearn
5 / 10 resultslearn Finasteride
Frontline, gold standard treatment for combatting androgenic alopecia
learn Bicalutamide
a nonsteroidal anti-androgen, most commonly used orally for women
learn Rapamycin
mTOR regulator and immunosuppressant used more recently for anti-aging and hair regrowth
learn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
Research
5 / 1000+ results
research Minoxidil Dose Response Study in Female Pattern Hair Loss Patients Determined to Be Non-Responders to 5% Topical Minoxidil
Higher minoxidil dose helps hair growth in non-responders without side effects.
research Comparison of a New 5% Minoxidil Foam and Rogaine in the Treatment of Androgenetic Alopecia in Chinese Men: A Randomized, Double-Blind, Phase III, Equivalence Trial
The new 5% minoxidil foam is as effective and safe as Rogaine® for treating hair loss in Chinese men.
research Long-Term Efficacy of Topical Minoxidil in Male Pattern Baldness
Topical minoxidil effectively treats male pattern baldness and prevents hair loss.
research Effect of Ultraviolet Light on Topical Minoxidil-Induced Hair Growth in Advanced Male Pattern Baldness
UV light does not significantly affect minoxidil's ability to treat male pattern baldness.
research Efficacy and Safety of a New 5% Minoxidil Formulation in Male Androgenetic Alopecia: A Randomized, Placebo-Controlled, Double-Blind, Noninferiority Study
New 5% minoxidil formula safely and effectively treats male hair loss.
Community Join
5 / 371 resultscommunity Kintor Has Completed Enrollment in Phase II Clinical Trial of KX-826 (Pyrilutamide) for Treatment of Male AGA Patients in the US
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
community Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Kintor Pharma Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.
community pyrilutamide phase 2 results right here, thanks to user Glaringbooch
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.